Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX)

Q: What does CUSIP 501976104 represent in this 13F holders report?

CUSIP 501976104 is the security identifier for KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share used to aggregate holder disclosures.

Q: How many institutions held KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share in Q2 2026?

2 institutional investors reported KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share for Q2 2026. Use the holders table for investor-level position and value details.

CUSIP: 501976104

Q2 2026 13F Holders as of 30 Jun 2026

Security type / class: Equity / Common Stock, par value $0.00001 per share
Total 13F shares: 424,990
Total 13F value: $3,786,661
Share change: +137,043
SEC-reported price per share: $8.91
Number of holders: 2
Value change: +$1,221,053
Number of buys: 2
Shares outstanding: 56,833,213

Security key

501976104

Report period

Q2 2026

Institutions

Top holders

KYTX full security history Ownership snapshot Full 13F holder table Previous quarter: Q1 2026 Kyverna Therapeutics, Inc. SEC filings Kyverna Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Reporting periods

Holder history for CUSIP 501976104

Previous quarter: Q1 2026

Recent filing periods:

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

Ownership snapshot

Top reported holders of KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Westlake BioPartners Fund...

Disclosed value leader

Westlake BioPartners Fund...

Comparable rows

15/15

Latest evidence

31 Mar 2026

13D/G 3/4/5 13F Lead comparable stake: 7.8% 13D/G row: Westlake BioPartners Fund I, L.P. Showing 1-6 of 15 holder rows.

Quick read

Westlake BioPartners Fund I, L.P. leads the comparable SEC ownership view at 7.8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Westlake BioPartners Fund I, L.P.'s linked filing trail.

Comparable ownership Top 5

Westlake BioPartners Fund I, L.P. 7.8%

GordonMD Global Investments LP 7%

Northpond Ventures III, LP 6.1%

Bain Capital Life Sciences Opport... 5.4%

Westlake BioPartners Opportunity ... 1.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Westlake BioPartners Fund I, L.P.	13D/G 3/4/5 Dr. Beth C. Seidenberg ("Seidenberg") · 10%+ Owner 13D/G 3/4/5	7.8%	$43,778,216 4,657,257 shares	$0	31 Dec 2025
GordonMD Global Investments LP	13F 13D/G Company 13F 13D/G	7% from 13D/G	$36,632,779 4,244,818 shares	—	31 Mar 2026
Northpond Ventures III, LP	13D/G Michael P. Rubin 13D/G	6.1%	$28,531,978 3,466,826 shares	$0	31 Dec 2025
Bain Capital Life Sciences Opportunities III, LP	13D/G 13D/G	5.4%	$25,595,300 3,110,000 shares	$0	31 Dec 2025
Westlake BioPartners Opportunity Fund I, L.P.	3/4/5 10%+ Owner 3/4/5	1.5%	$6,519,877 869,317 shares	+$999,998	18 Dec 2025
GILEAD SCIENCES, INC.	13F 3/4/5 Company · 10%+ Owner 13F 3/4/5	7.3%	$35,608,407 4,126,119 shares	—	31 Mar 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

424,990

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders

111

Q2 2026 holders

Holder diff

-109

Investor	Q1 2026 Shares	Q2 2026 Shares	Share Diff	Share Chg %	Q1 2026 value	Q2 2026 value	Value change	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend